Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995321 | 0.88 | THRB (0.37) | TP53DHODHKDM4EHSD17B10PIK3CA | |
| SCHEMBL9995001 | 0.86 | POLB (0.44) | POLBTP53NOD1TNFNOD2 | |
| SCHEMBL9994913 | 0.75 | ADORA2A (0.45) | POLBTP53DHODHKDM4EHSD17B10 | |
| SCHEMBL12069446 | 0.75 | ALDH1A1 (0.43) | POLBTP53NOD1TNFNOD2 | |
| SCHEMBL7171285 | 0.74 | PIK3CD (0.56) | POLBKDM4EHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL9995050 | 0.74 | GSR (0.41) | TP53MAT2AKDM4EHSD17B10KMT2A | |
| SCHEMBL9995197 | 0.73 | PRMT5 (0.39) | POLBTP53MAT2AKDM4EHSD17B10 | |
| SCHEMBL9995275 | 0.73 | KDM4E (0.39) | POLBTP53MAT2AKDM4EHSD17B10 | |
| SCHEMBL9995059 | 0.70 | MCHR1 (0.46) | POLBTP53NOD1MAT2AMCHR1 | |
| SCHEMBL12068757 | 0.70 | PARP14 (0.34) | POLBTP53TNFMAT2APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582680-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157787-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157787-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | POLB 3048/4885TP53 1856/4885NOD1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.